Placebo Nasal Spray for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Apr 2017: Trial registered, NCT03119610
  2. 22 Sep 2017: Trial started, NCT03119610

The trials

NCT03119610: The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity

State
Completed
Phase
Phase 1 and Phase 2
People
23 taking part
Started
22 Sep 2017
Primary completion
17 Dec 2018
Arms
Placebo nasal spray
Results
Posted on the registry
Papers
doi:10.1016/j.jamda.2021.04.015
  1. 18 Apr 2017: Trial registered
  2. 22 Sep 2017: Trial started
  3. 17 Dec 2019: Trial completed
  4. 22 Oct 2020: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.